## UNITED STATES SECURITIES AND EXCHANGE COMMISSION August 13, 2018

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933

## Aridis Pharmaceuticals, Inc.

File No. 333-226232 - CF#35911

Aridis Pharmaceuticals, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1

registration statement filed on July 18, 2018, as amended.

Based on representations by Aridis Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.2	through December 31, 2019
Exhibit 10.3	through December 31, 2019
Exhibit 10.4	through December 31, 2019
Exhibit 10.5	through December 31, 2019
Exhibit 10.6	through December 31, 2019
Exhibit 10.7	through December 31, 2019
Exhibit 10.8	through December 31, 2019
Exhibit 10.9	through December 31, 2019
Exhibit 10.10	through December 31, 2019
Exhibit 10.11	through December 31, 2019
Exhibit 10.12	through December 31, 2019
Exhibit 10.13	through December 31, 2019

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary